Atlas Trials

Biomarker Study of Immune-mediated Mechanism of Action of Neoadjuvant Trastuzumab in HER2+ Breast Cancer Patients

Clinical trial NCT03144947 · UNKNOWN

Trial details

NCT number
NCT03144947
Sponsor
Gruppo Oncologico Italiano di Ricerca Clinica
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Cancer, Breast
Start date
2016-11-29
Primary completion
2021-03-15
Enrollment
65

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.